Literature DB >> 362571

Double-blind study of ketoprofen and indomethacin in juvenile chronic arthritis.

E Bhettay, A J Thomson.   

Abstract

Ketoprofen (Orudis; Maybaker), whose use has not previously been reported in choldren, was compared with indomethacin in a double-blind crossover trial in 30 children with juvenile chronic arthritis. Both drugs proved to be safe and effective analgesics and anti-inflammatory agents although indomethacin emerged as the preferred drug. Perhaps higher doses of ketoprofen would be safe and more effective. Side-effects were few and mild. The problems of patient compliance and the assessment of pain in children are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 362571

Source DB:  PubMed          Journal:  S Afr Med J


  5 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.

Authors:  Christopher Eccleston; Tess E Cooper; Emma Fisher; Brian Anderson; Nick Mr Wilkinson
Journal:  Cochrane Database Syst Rev       Date:  2017-08-02

Review 3.  Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

Authors:  Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2022-09-02       Impact factor: 3.930

Review 4.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

5.  Antipyretic effect of ketoprofen.

Authors:  S Celebi; M Hacimustafaoglu; D Aygun; E S Arisoy; Y Karali; S Akgoz; A N Citak Kurt; M Seringec
Journal:  Indian J Pediatr       Date:  2009-01-05       Impact factor: 1.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.